TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05217602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AC+ARwdC
Description: The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+ARwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+ARwdC group will be offered incentives for using their anchoring plan during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AC+RwdC
Description: The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+RwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+RwdC group will be offered incentives for meditating during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Calm Control (UC)
Description: The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the UC group will watch a video with information about the study and how to create an anchoring plan for their meditation habit. Participants in the UC group will be offered incentives for completing the baseline, post-intervention, and follow-up surveys.
Study: NCT05150457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNA035
Description: Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNA035
Description: Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNA035
Description: Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNA035
Description: Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNA035
Description: Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNA035
Description: Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
Study: NCT04973657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK0214
Description: API in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK0214
Description: API in capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: API in capsule
Study: NCT05125302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Matching Ubrogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Matching Ubrogepant
Description: Oral Tablet
Study: NCT06485401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189
Description: 45 mg per tablet, oral administration, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189
Description: 45 mg per tablet, oral administration, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189
Description: 45 mg per tablet, oral administration, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189
Description: 45 mg per tablet, oral administration, single dose.
Study: NCT05769777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
Study: NCT06089980

Intervention type: BEHAVIORAL
Intervention: Effects from acute kratom exposure
Description: Participants who regularly use commercial Kratom products will orally consume a known quantity of kratom under direct observation on first study day; following this, participants will stop kratom use for approximately 2 nights and 2.5 days for the duration of the study.
Study: NCT06356129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: Specified dose on specified days
Study: NCT05016375

Intervention type: OTHER
Intervention: Interview
Description: Interview with individuals with T2DM
Study: NCT05936814

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: cemented bicondylar PCL substituting total knee replacement

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: cemented bicondylar PCL substituting total knee replacement
Study: NCT06356129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Specified dose on specified days
Study: NCT05176717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-421a
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-421a
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-procedure
Description: Sham-procedure (no experimental drug administered)
Study: NCT05263518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with AcrySof IQ IOL implantation.
Description: Patients in this study will receive cataract surgery with AcrySof IQ IOL implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with TECNIS toric IOL implantation.
Description: Patients in this study will receive cataract surgery with TECNIS toric IOL implantation.
Study: NCT06598124

Intervention type: OTHER
Group type: OTHER
Intervention: Investigational Product (IP)
Description: 1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.

Intervention type: OTHER
Group type: OTHER
Intervention: Investigational Product (IP)
Description: 1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator Product (CP)
Description: 1 single dose of CP consisting in 400 mL of milk with lactose

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator Product (CP)
Description: 1 single dose of CP consisting in 400 mL of milk with lactose
Study: NCT06612489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback based dynamic-difficulty game
Description: A biofeedback based dynamic-difficulty serious game rooted in distraction therapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: fixed difficulty game
Description: A fixed difficulty serious game rooted in distraction therapy.
Study: NCT06612957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair of uterine cicatricial diverticulum
Description: Cut off the uterine cicatricial diverticular tissue in the lower portion of the uterus, and restore normal uterine muscle tissue.
Study: NCT06611969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility, plus specific training of the inspiratory muscles, 3 times a week, at a load between 50 and 80% of the maximum inspiratory pressure of each participant, after re-education of their diaphragmatic ventilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility.
Study: NCT06612112

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions
Study: NCT06611462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation (the STRONG programme)
Description: Participants screened positive for one or more SNAP factors and randomised to the intervention group will receive an individualised plan for prehabilitation of their specific SNAP factors.
Study: NCT06611670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with Active Sentry
Description: Surgical instrument that detects changes in intraocular pressure and allows rapid feedback to stabilize pressure during cataract surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cataract surgery
Description: Cataract surgery performed with high intraocular pressures
Study: NCT06613152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-IT201 Injection
Description: Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Study: NCT06612931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-lumen catheter-guided mini-forceps biopsy is performed first
Description: In ERCP procedures, catheter-guided mini-forceps biopsy is performed before biliary brush cytology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary brush cytology with vacuum aspiration is performed first
Description: In ERCP procedures, biliary brush cytology with vacuum aspiration is performed before dilation catheter-guided mini-forceps biopsy.
Study: NCT04888494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: For the brain stimulation the investigators will use Repetitive Transcranial Magnetic stimulation (rTMS). Different stimulation conditions (hippocampal or sham) will be delivered in each round of stimulation (5 days). Repetitive TMS will be applied at 100% resting motor threshold intensity, 20 Hz pulse trains separated by 28-s inter-train intervals (\~20 minutes for the entire daily stimulation session). Stimulation parameters will be identical in both groups

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: Sham rTMS
Study: NCT04052321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D optical surface scan
Description: A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
Study: NCT06356129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Specified dose on specified days
Study: NCT05592418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: 100 to 400 mg twice weekly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Normal Saline
Description: 40 to 160 mL twice weekly
Study: NCT06333392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total underwater colonoscopy
Description: one grooup will be randomized to receive a total underwater colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy
Description: one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal
Study: NCT04816461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine Sulfadoxine-Pyrimethamin administration
Description: SMC treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine Sulfadoxine-Pyrimethamin administration
Description: SMC treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Roommates treatment if they are positive to malaria

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard HRP2-RDT
Description: Roommates screening with standard HRP2-RDT
Study: NCT04995419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Intravenous Infusion
Study: NCT06220643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: Progressive resistance exercise for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide plus lidocaine
Description: 40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide plus lidocaine
Description: 40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%)
Study: NCT06127160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Cephalexin 1000 mg by mouth 3 times daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin or placebo
Description: Cephalexin 1000 mg by mouth 3 times daily for a minimum of 3 days, once participant reports symptom resolution for 24 hours they will switch to placebo for remainder of 10 days of treatment.
Study: NCT05044793

Intervention type: DEVICE
Intervention: OMNI® Surgical System
Description: The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

Intervention type: DEVICE
Intervention: OMNI® Surgical System
Description: The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
Study: NCT02670447

Intervention type: PROCEDURE
Intervention: MRI
Description: Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
Study: NCT05018585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
Description: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colecalciferol 2000 IU
Description: Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Colecalciferol 2000 IU
Description: Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Diamyd, Alhydrogel® only
Study: NCT06390995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-853
Description: TAK-853 intravenous injection
Study: NCT06425198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days
Study: NCT05731427

Intervention type: DIAGNOSTIC_TEST
Intervention: Pseudomonas aeruginosa colonization infection
Description: With or without airway Pseudomonas aeruginosa colonization infection

Intervention type: DIAGNOSTIC_TEST
Intervention: Pseudomonas aeruginosa colonization infection
Description: With or without airway Pseudomonas aeruginosa colonization infection

Intervention type: DRUG
Intervention: Macrolides
Description: Before or after 6 months of treatment with macrolides for patients with bronchiectasis

Intervention type: DRUG
Intervention: Macrolides
Description: Before or after 6 months of treatment with macrolides for patients with bronchiectasis
Study: NCT06542081

Intervention type: BEHAVIORAL
Intervention: Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.
Description: Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.
Study: NCT05307861

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic duct stenting with plastic stent
Description: Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic duct stenting with plastic stent
Description: Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic duct stenting with Biodegradable Stent
Description: Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic duct stenting with Biodegradable Stent
Description: Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
Study: NCT04857619

Intervention type: OTHER
Intervention: None (Observational study)
Description: The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).
Study: NCT04808089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Lung App. of mobile phone+ezOxygen mobile spirometry
Description: Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~The physicians can get the information about control status, lung function, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The research assistant assess/ teach inhaler technique, offering advice on adherence, delivering patient self-management asthma action plan and education the meaning of asthma control accessed by ACT.
Study: NCT04867525

Intervention type: OTHER
Intervention: Physician's choice according to patient's needs.
Description: Routine care as per site standard.
Study: NCT05262621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation
Description: Practice muscle relaxation for 20 minutes once/a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to relaxing music once/day
Description: Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes
Study: NCT05802940

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic health record best practice alert
Description: The electronic health record will identify patients at high-risk for preeclampsia and candidate for low dose aspirin (LDA) prophylaxis. For those in the intervention group, a best practice alert will notify the healthcare provider within the patient's chart during a prenatal visit that LDA should be recommended.
Study: NCT05521074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.
Study: NCT05226910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS and intensive therapies
Description: This intervention will consist in the combination of tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham and intensive therapies
Description: This intervention will consist in the combination of sham tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
Study: NCT05521074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid. tDCS will not be active in this condition.
Study: NCT05095194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with IOL implantation and with/without capsular tension ring implatation
Description: Patients in this study will receive cataract surgery with IOL implantation and capsular tension ring implantation or cataract surgery with IOL implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with IOL implantation and with/without capsular tension ring implatation
Description: Patients in this study will receive cataract surgery with IOL implantation and capsular tension ring implantation or cataract surgery with IOL implantation